The bioconjugate triazole 28 was prepared from precursors derived from a PMO azide with known in vivo efficacy as a splice-switching oligonucleotide for the treatment of Spinal Muscular Atrophy (SMA) and a peptide fragment derived from a portion of the ApoE protein50. Here, APOE is linked to spinal muscular atrophy.